Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2236 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2236 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Rheumatology
JIA Toolbox Feasibility Study
Testing three prototype tools to help children with juvenile arthritis manage daily activities more independently and effectively.
22 Apr 2026 NCT07543575
● Recruiting Phase I Neurology
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Treatment being tested: AZD0120, a dual-targeting CAR-T cell therapy designed to target both BCMA and CD19 on B cells, being evaluated for safety and…
22 Apr 2026 NCT07224373
● Recruiting Phase II
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
ALXN1920 (a complement C3 inhibitor) is being tested against placebo in adults with primary membranous nephropathy, with efficacy measured by reduction in 24-hour urine…
22 Apr 2026 NCT07157787
● Recruiting Phase II
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Drug being tested: ADX-038, a novel therapeutic agent targeting complement-mediated pathways, is being evaluated for safety, efficacy, and how the body processes and responds…
22 Apr 2026 NCT06989359
● Recruiting Respiratory / COPD / Asthma
The Physiotherapy Assessment of Breathing Pattern Disorder
What is being tested: The study evaluates the Breathing Pattern Assessment Tool (BPAT), a clinical assessment instrument designed by physiotherapists to diagnose and characterise…
22 Apr 2026 NCT07543588
● Recruiting Phase III Oncology
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Drug being tested: GSK5764227 (Risvutatug rezetecan/Ris-Rez) is a novel B7-H3-targeted therapy designed to inhibit cancer cell growth and metastasis in patients with relapsed small…
22 Apr 2026 NCT07099898
● Recruiting Phase III Cardiology / Cardiovascular
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial – Part 2
What is being tested: Recombinant Factor VIIa (rFVIIa) as a potential therapeutic intervention to halt hematoma expansion and improve outcomes in patients with acute…
22 Apr 2026 NCT07227246
● Recruiting Cardiology / Cardiovascular
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Device Being Tested: The Shockwave Reducer, a coronary sinus reducer device designed to increase coronary perfusion pressure and improve myocardial blood flow in patients…
22 Apr 2026 NCT05102019
● Recruiting Phase III Cardiology / Cardiovascular
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
What is being tested: ADX-324, a novel therapeutic agent, is being evaluated in a Phase 3 trial to assess its efficacy and safety in…
22 Apr 2026 NCT06960213
● Recruiting Cardiology / Cardiovascular
Collection of Blood Samples for New Diagnostic Devices 2
What is being tested: Development and validation of new diagnostic biomarkers on the LumiraDx Platform, with comparative evaluation against established gold standard reference methods…
22 Apr 2026 NCT05568966
● Recruiting Phase I Oncology
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Drug Being Tested: NDI-219216, a novel investigational agent being evaluated for safety, tolerability, and efficacy in patients with advanced solid tumours through a phased…
22 Apr 2026 NCT06898450
● Recruiting Phase III Oncology
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What is being tested: BGB-16673, a novel BTK inhibitor, is being evaluated against pirtobrutinib (an established BTK inhibitor) in patients with relapsed/refractory CLL or…
22 Apr 2026 NCT06973187
● Recruiting Phase III Oncology
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
What is being tested: This Phase 3 trial compares belantamab mafodotin combined with lenalidomide and dexamethasone (BRd) against daratumumab combined with lenalidomide and dexamethasone…
22 Apr 2026 NCT06679101
● Recruiting Phase III Oncology
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Treatment being tested: IMVT-1402, a novel therapeutic agent, is being evaluated for efficacy, safety and tolerability in adults with generalized myasthenia gravis across mild…
22 Apr 2026 NCT07039916
● Recruiting Phase III Oncology
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
What is being tested: Zanubrutinib (a Bruton tyrosine kinase inhibitor) combined with obinutuzumab (anti-CD20 monoclonal antibody) versus the standard regimen of lenalidomide plus rituximab…
22 Apr 2026 NCT05100862
● Recruiting Phase III Oncology
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
What is being tested: A novel oral cladribine formulation is being evaluated against placebo for efficacy and safety in treating generalized myasthenia gravis (gMG),…
22 Apr 2026 NCT06463587
● Recruiting Phase III Oncology
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)
Treatment being tested: Petosemtamab (a fibroblast activation protein inhibitor) combined with pembrolizumab compared to pembrolizumab monotherapy as first-line treatment for recurrent or metastatic head…
22 Apr 2026 NCT06525220
● Recruiting Phase II
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
AGA2115 tested against placebo in adults with osteogenesis imperfecta caused by COL1A1 or COL1A2 gene mutations.
21 Apr 2026 NCT07062588
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
A new drug (claseprubart) tested against placebo in adults with chronic inflammatory demyelinating polyneuropathy to assess whether it works and is safe.
21 Apr 2026 NCT06858579
active not recruiting Rheumatology
Resistance Exercise Training to Improve Bone and Articular Cartilage Health in Women
Resistance exercise with varying intensity and speed improves bone density, cartilage health, and muscle strength in women.
21 Apr 2026 NCT05889598
active not recruiting Phase III
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
ALXN1720 (a complement inhibitor) was tested for safety and effectiveness in treating autoimmune myasthenia gravis in adults.
21 Apr 2026 NCT05556096
● Recruiting Phase III
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Anifrolumab injection added to standard treatment improved muscle disease activity in adults with polymyositis and dermatomyositis compared to placebo.
21 Apr 2026 NCT06455449
active not recruiting Rheumatology
Comprehensive Nano – Post Market Clinical Follow-Up Study
Single-arm study tracking long-term safety and effectiveness outcomes of Comprehensive Nano devices to meet regulatory requirements.
21 Apr 2026 NCT03423953
active not recruiting Phase III Oncology
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Trial comparing a biosimilar copy of Keytruda with the original drug in advanced lung cancer patients to confirm equivalent effectiveness.
21 Apr 2026 NCT06311721
active not recruiting Phase I / Phase II Oncology
Durvalumab and Tremelimumab for Pediatric Malignancies
Study testing safe doses of two immunotherapy drugs in children with advanced cancers, then checking if they work.
21 Apr 2026 NCT03837899
active not recruiting Phase III Gastroenterology
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn’s Disease
Guselkumab (IL-23 inhibitor) tested for treating perianal fistulas in Crohn's disease patients, measuring effectiveness and safety.
21 Apr 2026 NCT05347095
● Recruiting
Impact of CMG vs VCMG in Recurrent Stress Incontinence- A Pilot Study
A pilot study comparing standard urodynamic testing versus video-urodynamic testing to guide surgery for women with recurrent stress incontinence after previous failed surgery.
21 Apr 2026 NCT07542080
● Recruiting Respiratory / COPD / Asthma
Children’s Health, Respiratory Inflammation and Short-term Air Pollution
What is being tested: Whether physical activity during periods of high air pollution exposure causes greater respiratory inflammation in children compared to remaining at…
21 Apr 2026 NCT07431021
● Recruiting Phase III Oncology
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Treatment being tested: Saruparib (AZD5305), a PARP inhibitor, combined with standard radiotherapy and androgen deprivation therapy versus placebo in men with high-risk and very…
21 Apr 2026 NCT06952803
● Recruiting Neurology
Large Language Model for Understanding and Monitoring Elderly Neurocognition
What is being tested: A large language model (AI system) designed to analyse collateral histories from family members and caregivers to help understand and…
21 Apr 2026 NCT07347431
● Recruiting Phase III Neurology
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer’s Disease (ADEPT-5)
Treatment being tested: KarXT + KarX-EC combination therapy, a novel muscarinic M1/M4 receptor agonist approach, being evaluated specifically for psychosis symptoms in Alzheimer's disease…
21 Apr 2026 NCT06947941
● Recruiting Phase III Respiratory / COPD / Asthma
Randomised Evaluation of COVID-19 Therapy
What is being tested: RECOVERY is evaluating multiple therapeutic interventions (antivirals, immunomodulators, corticosteroids, and other agents) in hospitalised pneumonia patients, with the primary aim…
21 Apr 2026 NCT04381936
● Recruiting Cardiology / Cardiovascular
Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation
What is being tested: This prospective observational study evaluates clinical phenotypes and predictive factors for functional mitral and tricuspid regurgitation in atrial fibrillation patients,…
21 Apr 2026 NCT05920824
● Recruiting Oncology
Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates – UK
Device being tested: The Creo Medical MicroBlate Flex instrument delivers microwave energy via bronchoscopy to ablate (heat and destroy) lung tumour tissue in patients…
21 Apr 2026 NCT06869122
● Recruiting Phase III Oncology
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
What is being tested: The trial compares R-mini-CHOP chemotherapy (2 cycles) followed by AZD0486 versus standard R-mini-CHOP (6 cycles) as first-line treatment for large…
21 Apr 2026 NCT07215585
● Recruiting Phase I Oncology
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
What is being tested: AZD3470, an investigational oral agent, is being evaluated as both a standalone treatment and in combination with other anticancer drugs…
21 Apr 2026 NCT06137144
● Recruiting Phase III Oncology
SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Treatment Being Tested: IMA203, a novel immunotherapy agent, is being compared against investigator's choice of standard treatments (such as checkpoint inhibitors or chemotherapy) in…
21 Apr 2026 NCT06743126
● Recruiting Phase II Rheumatology
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Tulisokibart (MK-7240) is being tested to see if it can improve symptoms of radiographic axial spondyloarthritis better than placebo.
20 Apr 2026 NCT07133633
active not recruiting Phase III Cardiology / Cardiovascular
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) – ACCLAIM-Lp(a)
Lepodisiran injection reduces heart attacks and strokes in patients with high lipoprotein(a) levels and existing heart disease.
20 Apr 2026 NCT06292013
active not recruiting Phase II
Extended Access of Momelotinib in Adults With Myelofibrosis
Momelotinib Extended Access Trial Summary This study provides ongoing access to momelotinib for myelofibrosis patients and monitors long-term safety and survival.
20 Apr 2026 NCT03441113
active not recruiting
The Use of DXA in Scoliosis
Pilot study testing whether lying-down DXA scans can accurately measure scoliosis curves and help with brace design compared to standard standing X-rays.
20 Apr 2026 NCT06512038
active not recruiting
Single Palatal Temporary Anchorage Device for Anterior Open Bite
A single palatal screw was as effective as two cheek screws for closing open bites using fixed braces.
20 Apr 2026 NCT04419805
active not recruiting Phase I / Phase II
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
BION-1301 was tested for safety and tolerability in healthy people and IgA kidney disease patients.
20 Apr 2026 NCT03945318
● Recruiting Phase III Oncology
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
What is being tested: PF-06821497 (mevrometostat), a novel investigational medicine, combined with enzalutamide versus standard treatments (enzalutamide alone or docetaxel chemotherapy) in men with…
20 Apr 2026 NCT06551324
● Recruiting Phase I Oncology
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
What is being tested: RO7656594, a novel investigational agent, is undergoing evaluation for its safety profile, tolerability, pharmacokinetics (drug behaviour in the body), and…
20 Apr 2026 NCT05800665
● Recruiting Phase III Oncology
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
What is being tested: Capivasertib (AKT inhibitor) combined with CDK4/6 inhibitors and fulvestrant compared to CDK4/6 inhibitors and fulvestrant alone in advanced/metastatic HR+/HER2- breast…
20 Apr 2026 NCT04862663
● Recruiting Phase II Oncology
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
What is being tested: Novel therapeutic interventions and their combinations for colorectal cancer treatment, with primary focus on evaluating safety profiles and clinical efficacy…
20 Apr 2026 NCT06792695
● Recruiting Phase II Rheumatology
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
What is being tested: Iptacopan (LNP023), a complement factor B inhibitor, is being evaluated as an add-on therapy to standard care in patients with…
20 Apr 2026 NCT05268289
● Recruiting Phase III Respiratory / COPD / Asthma
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
What is being tested: A single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) compared to placebo in recently diagnosed COVID-19 patients, evaluating both safety…
20 Apr 2026 NCT04910269
● Recruiting Phase III Oncology
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
What is being tested: Obrixtamig (a DLL3-targeting agent) combined with atezolizumab, carboplatin, and etoposide versus standard chemotherapy alone in adults with advanced small cell…
20 Apr 2026 NCT07472517